Omnibus proteome-wide association study (PWAS-O) identified 43 risk genes for Alzheimer's disease dementia

Tingyang Hu[1,2], Randy L. Parrish[1,2], Aron S. Buchman[3], Shinya Tasaki[3], David A. Bennett[3], Nicholas T. Seyfried[4], Michael P. Epstein[1], Jingjing Yang[1*]

1. Center for Computational and Quantitative Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA
2. Department of Biostatistics and Bioinformatics, Emory University School of Public Health, Atlanta, GA, 30322, USA
3. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, 60612, USA
4. Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA

[*] Correspondence Author: jingjing.yang@emory.edu

Abstract

Proteome-wide association study (PWAS) integrating proteomics data with GWAS summary data is a powerful tool to identify risk genes for complex diseases. These genes can inform disease mechanisms with genetic effects mediated through protein abundance. We propose a novel omnibus method to further improve PWAS power by modeling unknown genetic architectures with multiple statistical models. We applied TIGAR, PrediXcan, and FUSION to train protein abundance imputation models for 8,430 proteins from dorsolateral prefrontal cortex with whole genome sequencing data (n=355). Next, the trained models were integrated with GWAS summary data of Alzheimer's disease (AD) dementia (n=~70K) to conduct PWAS. Last, we employed the Aggregated Cauchy Association Test to obtain omnibus PWAS (PWAS-O) p-values from these three tools. PWAS-O identified 43 risk genes of AD dementia that were interconnected into a protein-protein interaction network including *TOMM40*, *APOC1*, and *APOC2*. It detected 5 novel genes missed by GWAS and TWAS. PWAS-O can be applied to characterize underlying genetic mechanisms for diverse diseases.

Main

Recent large-scale genome-wide association studies (GWAS) of Alzheimer's disease (AD)

dementia have identified 38 risk loci[1], but little is known about their underlying mechanisms that lead to

clinical Alzheimer's disease. Integrating transcriptomics with GWAS summary data has been shown an

effective approach for identifying potential causal risk genes of complex human diseases (e.g., AD

dementia). This approach can also inform on potential underlying disease mechanisms as the identified

genetic effects may be potentially mediated via gene expression[2-5]. Since many biological processes can

affect protein abundance, gene expression levels are not the optimal proxy for elucidating the role of

proteins in disease mechanisms. A protein-based approach that considers the effects of genetic variations

on alterations in protein abundance has the potential to identify novel genetic risk loci linked to disease

via proteins that may not be identified by GWAS and TWAS[6-9].

Proteome-wide association study (PWAS) that integrates proteomics data with GWAS summary

data has also shown promise for studying complex traits and diseases[10-12]. Since gene expression and

protein abundance are both molecular quantitative traits that might mediate genetic effects, existing

TWAS tools can be applied to train protein abundance imputation models using genetic variants as

predictors from a reference panel. Genetic effect sizes in the imputation models could be viewed as effect

sizes of "protein quantitative trait locus (pQTL)" in a broad sense (as these "pQTL" are not necessarily

statistically significant), which would be taken as variant weights for gene-based association study (i.e.,

PWAS) with GWAS data.

Existing TWAS tools use various statistical regression models to train imputation models of

quantitative molecular traits, and each tool has its own advantage for modeling a specific type of genetic

architecture underlying the molecular trait of interest. For example, PrediXcan[13] uses a penalized linear

regression model with Elastic-Net penalty[14] which has the advantage of modeling sparse genetic

architecture. TIGAR[7] implements the nonparametric Bayesian latent Dirichlet process regression (DPR)

which has been shown effective to model the infinitesimal genetic architecture[15]. FUSION[4] uses

penalized linear regression model with Elastic-Net penalty and LASSO penalty[16], regular linear

regression model with best unbiased linear predictor (BLUP), single variant model with Top eQTL or

pQTL (Top1), and Bayesian spare linear mixed model (BSLMM)[17], and then selects the best model for

PWAS based on cross-validation (CV) R^2 from model training.

Even though the FUSION tool employs multiple regression models, it only uses the model with

top performance based on reference data. Rather than considering a single statistical method to train

molecular QTL weights, there is strong evidence that combining association test p-values based on

multiple statistical methods using the Aggregated Cauchy Association Test[18] (ACAT) can increase power,

as demonstrated in recent TWAS[19] studies. Therefore, we applied ACAT to aggregate PWAS p-values

obtained by TIGAR, PrediXcan, and FUSION and subsequently derive an omnibus PWAS (PWAS-O) p-

value. PWAS-O is expected to improve PWAS power compared to PWAS based on a single imputation

model of protein abundances, since PWAS-O better accounts for the unknown genetic architecture of

protein abundances for a given gene.

To test our approach, we applied PWAS-O to study AD dementia by leveraging reference human

proteome-wide data of dorsolateral prefrontal cortex (DLPFC) of 355 cognitively well-characterized older

decedents with whole genome sequencing (WGS) genetic data, and summary data from the most recent

GWAS of AD dementia (n=762,917, excluding 23&me samples)[1]. Next, we examined the protein-protein

interaction (PPI) network among the identified PWAS risk genes of AD dementia. We identified 43 risk

genes of AD dementia by PWAS-O that were connected into a protein-protein interaction (PPI) network

involving the well-known risk gene *APOE* of AD dementia. We validated the potential causality of 27 out

of 43 (63%) PWAS risk genes by probabilistic Mendelian randomization (PMR-Egger)[20] and summary

data-based Mendelian randomization (SMR)[21, 22] tool.

Results

<u>**Omnibus PWAS (PWAS-O)**</u>

Similar to the standard two-stage PWAS/TWAS method (**Fig. 1** and **Fig. 2**)[23], protein abundance

imputation models are first trained in Stage I to obtain effect size estimates of genetic variants/predictors

(i.e., pQTL weights), by TIGAR[23] (nonparametric Bayesian DPR), PrediXcan[13] (Elastic-Net), and

FUSION[4] (Elastic-Net, LASSO, BLUP, Top1). Genetic variants within ±1MB around the transcription

starting and termination sites of the corresponding coding gene were considered as predictors in the

imputation models. In Stage II, these trained pQTL weights (coefficients of these genetic variant

predictors) are used along with GWAS data to conduct gene-based association tests. For each protein-

coding gene, PWAS p-values will be respectively obtained by using the pQTL weights estimated by

TIGAR, PrediXcan, and FUSION, which will then be combined by ACAT to generate the corresponding

PWAS-O p-value. We present the PWAS-O framework in **Fig. 2**. Both individual-level and summary-

level GWAS data can be used in Stage II. A reference panel of the same ancestry as the GWAS data can

be used to provide LD information for gene-based association tests in Stage II. The TIGAR[23] tool

provides functions to calculate LD covariance matrices and conduct gene-based association tests.

ROS/MAP Proteomics and WGS data

The human brain proteomic profiles were generated from the DLPFC of postmortem brain

samples donated by 400 participants of European ancestry of the Religious Orders Study/Memory and

Aging Project (ROS/MAP)[10, 24]. The human proteome abundance data underwent quality control (**Fig. S1**)

that regressed out the effects of technical factors and confounding covariates including age at death, sex,

postmortem interval, and study (ROS or MAP) (see details in the Methods). As a result, we obtained the

proteome abundance data of 8,430 proteins. After quality control of these proteome data, 355 individuals

also had WGS data profiled[25]. The proteome abundance and WGS data of these 355 individuals were used

as a reference panel for our PWAS-O study of AD dementia.

Protein abundance imputation models

At training Stage I, five-fold cross-validation was conducted to evaluate the training

performance per statistical model. The protein abundance imputation models with 5-fold CV R^2 >0.5%

were retained and their estimated pQTL weights would be used to conduct PWAS. As suggested by the

TIGAR tool[23], the threshold of 5-fold CV R^2 >0.5% was arbitrarily chosen to allow a greater number of

genes to be tested by the follow-up gene-based association study (i.e., PWAS). The threshold of CV R^2

would not affect the statistical validity of the test statistic used in the follow-up PWAS.

113   As shown in **Table 1**, 6673 protein abundance imputation models were retained by TIGAR

114   with median CV R^2 = 0.013; 1835 protein abundance imputation models were retained by PrediXcan

115   with median CV R^2 = 0.0094; and 2173 protein abundance imputation models were retained by FUSION

116   (the best model selected out of LASSO, Elastic-Net, BLUP, Top1 models with the highest CV R^2) with

117   median CV R^2 = 0.0093. Histograms of the CV R^2 obtained by these three tools were presented in **Fig.**

118   **S2**.

119
120   **PWAS-O results of AD dementia**
121
122   As described in the above paragraph about the PWAS-O framework, we first conducted PWAS

by employing TIGAR[23], PrediXcan[13], and FUSION[4] tools, using the ROS/MAP reference proteomics data

of DLPFC and the most recent GWAS[1] summary data of AD dementia (n=762,917). That is, the

estimated pQTL effect sizes in these trained protein abundance imputation models were taken as variant

weights to conduct gene-based association tests using the GWAS summary data (**Fig. S3**). Second, we

implemented ACAT[18] to obtain PWAS-O p-values from the PWAS p-values by these three tools. Our

PWAS-O approach identified 43 significant genes with false discovery rate (FDR) (i.e., q-value) <0.05,

which could affect the risk of AD dementia through their genetic effects on the corresponding protein

abundances (**Fig. 3, Fig. S4**). We curated 19 independent genes from these 43 significant genes (**Table 2,**

Table S1), by considering only the most significant genes among all significant genes with shared test

regions (±1MB around the test transcription starting and termination sites of the protein-coding gene).

133   We found 10 out of these 43 PWAS risk genes were detected by previous GWAS studies from

GWAS Catalogue[26], including *AGFG2*[27], *CLPTM1*[28], *PVR*[28], *PVRL2*[28], *APOC1*[29], *APOC2*[30], *CKM*[28],

ERCC1[31], *OPA3*[31], and *SYMPK*[31]. PWAS risk genes *CDC42*[32], *MAP3K7*[33], and *FNBP4*[32] were found

associated with cognitive ability in previous GWAS studies. PWAS risk genes *CCDC86*[34]*, KIF18B*[34],

PPM1N[34]*,* and *RTN2*[34] were found associated with neurofibrillary tangles (a key clinical indicator of AD)

measurement by GWAS studies. Additionally, 13 out of 43 significant AD PWAS genes (*ZYX*[35]*,*

C1QTNF4[36]*, FNBP4*[35]*, PVR*[8]*, PVRL2*[36]*, TOMM40*[8]*, APOC1*[9]*, APOC2*[37]*, CLPTM1*[36]*, ERCC1*[38]*, OPA3*[38]*,*

EML2[9] and *DMWD*[35]) were significant risk genes of AD by previous TWAS.

Our PWAS-O findings not only replicate significant risk genes identified by previous GWAS

and TWAS, but also identify novel risk genes for AD dementia. PWAS-O identified 5 novel risk genes

that were neither detected by GWAS nor TWAS (*MGAT5, PACSIN3*, *PLA2G7, DIABLO, YWHAB*). The

novel gene *PLA2G7* was shown to have biological function involved in inflammatory and oxidative

activities[39], and with a known association with AD and cognitive decline[40]. The novel gene *PACSIN3* has

been implicated in the disorders of the central nervous system such as schizophrenia[41].

<u>pQTL weights by different regression models</u>

To investigate the genetic architecture underlying protein abundances, we plotted the pQTL

weights estimated by TIGAR (DPR), PrediXcan (Elastic-Net), and FUSION (best model out of LASSO,

Elastic-Net, BLUP, Top1) for significant PWAS risk genes *PPM1N* and *DCAKD* in **Fig. 4**. Generally,

TIGAR and FUSION had non-zero pQTL weights estimated for almost all test SNPs within the test

region, for using a model assuming infinitesimal genetic architecture[15]. Whereas, PrediXcan had much

fewer non-zero pQTL weights estimated for assuming a sparse genetic architecture and enforcing variable

selection. For example, *PPM1N* was a significant risk gene identified by both TIGAR and FUSION

(**Table 2**), which has hundreds of test SNPs with non-zero pQTL weights (by both TIGAR and FUSION)

that were colocalized with significant GWAS signals (colored dots in **Fig. 4A**). Gene *DCAKD* was only

found significant by FUSION (p-value $= 3.12 \times 10^{-5}$) but not by TIGAR (p-value $= 3.62 \times 10^{-3}$), for

having fewer test SNPs of relatively large magnitude of pQTL weights that were colocalized with

significant GWAS signals (**Table2, Fig. 4B**).

Similarly, comparing pQTL weights obtained by TIGAR to PrediXcan for significant PWAS

genes *MBLAC1* and *MRPL16* (**Fig. S5**), we observed that less than 10 test SNPs had non-zero pQTL

weights by PrediXcan, versus thousands of test SNPs with non-zero pQTL weights by TIGAR. Because

PrediXcan estimated zero pQTL weights for most SNPs with significant GWAS p-values in the test

region of gene *MRPL16* (**Table 2**, **Fig. S5A**), *MRPL16* was only found significant by TIGAR (p-value =

4.33×10^{-15}). Whereas, when both TIGAR and PrediXcan estimated non-zero pQTL weights for SNPs

with significant GWAS p-values in the test region of gene *MBLAC1* (Table S1, Fig. S4B), it was

identified significant by both TIGAR (p-value = 7.31×10^{-5}) and PrediXcan (p-value = 3.49×10^{-4}).

These scatterplots of pQTL weights of PWAS risk genes showed that significant PWAS genes

were mainly driven by test SNPs that had colocalized pQTL weights and significant GWAS signals.

Because the underlying genetic architectures of protein abundances are unknown in practice, no single

statistical model would lead to superior PWAS power across genome-wide protein-coding genes. Our

proposed PWAS-O approach is expected to gain power in practice for considering multiple statistical

models per protein-coding gene.

PPI network among PWAS risk genes of AD dementia

Next, we used STRING[42, 43] to investigate the PPI network among these 43 PWAS risk genes of

AD dementia, by using public data sources of protein interactions. Based on evidences from curated

databases, experiments, text mining, co-expression, gene fusions, and protein homology[42], STRING

clustered 23 out of these 43 PWAS risk genes into 4 communities (**Fig. 5**). Different data sources of the

protein-protein connection were depicted by differently colored connection edges. It is interesting to see

that the largest community of these PWAS risk genes is a network involving genes *TOMM40*, *APOC1*,

and *APOC2* that are located nearby the well-known risk gene *APOE* of AD dementia, and are known to

be associated with both AD dementia and low-density lipoprotein levels[44].

STRING also provided gene enrichment analysis results with respect to Gene Ontologies (GO)

and KEGG. We observed that these 43 PWAS risk genes were enriched for the GO terms of UV

protection (*ERCC1, ERCC2, ERCC3*), transcription-coupled nucleotide-excision repair (*ERCC1, ERCC2,*

ERCC3, PRPF19), plasma lipoprotein particle remodeling (*APOC1, APOC2, PLA2G7*), negative

regulation of very-low-density lipoprotein particle clearance (*APOC1, APOC2*), protein-containing

complex subunit (*MRPL16, ATPAF2, KIF18B, ERCC2, ERCC3, PRPF19, APOC1, APOC2, PLA2G7*),

and the KEGG pathway of adherens junction (*MAP3K7*, *CDC42*, *PVRL2*).

Interestingly, novel PWAS risk genes *ERCC3*, *ERCC2* and *PRPF19* are closely interconnected

with a known GWAS/TWAS risk gene *ERCC1* in the PPI network (based on evidence from curated

databases, co-expression and textmining) and enriched in nucleotide-excision repair pathway. Novel

PWAS risk gene *PLA2G7* connects with *APOC1* and *APOC2* in the PPI network and involves in the

plasma lipoprotein particle remodeling pathway.

These PPI network analysis results showed that the list of identified risk genes by PWAS-O were

connected with known risk genes of AD dementia and enriched in AD related pathways.

Examine causal and pleiotropy effects of PWAS risk genes

We applied both probabilistic Mendelian randomization (PMR-Egger)[20] and summary data-based

Mendelian randomization (SMR)[45] methods to test if the causal genetic effects on AD dementia were

mediated through protein abundance in the possible presence of horizontal pleiotropy. Horizontal

pleiotropy means that genetic effects on AD dementia and on protein abundances were originated from

the same SNPs but through different pathways (i.e., with no mediation effects). PMR-Egger suggested

that 25 out of 43 PWAS risk genes have significant causal effects (FDR<0.05) on AD dementia after

controlling for potential horizontal pleiotropy effects, including 6 genes (*PVRL2*, *TOMM40*, *APOC1*,

RTN2, OPA3, EML2) nearby the *APOE* region that also have significant horizontal pleiotropy effects with

FDR<0.05. Similarly, the method of SMR with its accompanying heterogeneity in dependent instruments

(HEIDI) test found that 22 out of 43 PWAS risk genes have potential causal effects on AD dementia with

FDR<0.1, of which 20 genes were overlapped with 25 causal genes detected by PMR tool. These results

validated potential causal genetic effects that were mediated through protein abundances for 27 (63%)

PWAS risk genes identified by PWAS-O.

Compare with TWAS results of AD dementia

To determine whether the 43 PWAS risk genes had similar evidence at the transcript level, we

also conducted TWAS of AD dementia based on the ROS/MAP reference data using TIGAR and

PredXican. From TWAS p-values by these two tools, we obtained omnibus TWAS (TWAS-O) p-values

by ACAT. We found that 34 out of 43 PWAS risk genes (79%) were either detected by TWAS with

FDR<0.05, or located within 1MB of TWAS risk genes (**Table S2**). These results showed that majority

PWAS risk genes had genetic effects on phenotype that were mediated through both transcriptome and

proteome.

Discussion

In this work, we propose an omnibus PWAS approach (PWAS-O) that improves power for better

modeling of the unknown genetic architecture of proteome abundances. By aggregating PWAS p-values

obtained from several available tools — TIGAR, PrediXcan, and FUSION, our PWAS-O approach

identified 43 risk genes for AD dementia, by using the ROS/MAP reference proteomics data and the most

recent GWAS summary data of AD dementia. These identified PWAS risk genes may be linked to AD

dementia via protein abundances. From STRING analysis, we showed that out of these 43 PWAS

significant risk genes, 9 genes were enriched in the pathway of protein-containing complex subunit; 4

genes were enriched in the gene ontology pathway of transcription-coupled nucleotide-excision repair; 3

genes were enriched in the pathway of plasma lipoprotein particle remodeling. Compared to TWAS

results using the same GWAS summary data, 34 out of 43 significant PWAS risk genes were either

TWAS risk genes or within 1MB region of TWAS risk genes. These results showed that PWAS risk

genes identified by our PWAS-O approach are part of key biological pathways involving brain functions.

The genes and proteins identified may be high-value therapeutic targets for further drug discovery as well

as for mechanistic studies that can advance our understanding of the biology driving AD dementia in

aging brains.

Notable biological roles for these identified PWAS risk genes include lipoprotein metabolism,

inflammatory reactions, DNA repair, pre-mRNA splicing, and mitochondrial function. For example,

APOC1 and *APOC2*, located in a gene cluster on chromosome 19 including the well-known AD risk gene

APOE[46-48], play important roles in the development of lipoprotein metabolism[44]. Especially, *APOE* is an

intensively studied risk gene of AD and plays an essential role in the central nervous system[49, 50].

Connected with *APOC1* and *APOC2,* as shown in the PPI of our identified PWAS risk genes, *PLA2G7* is

a novel AD risk gene identified by PWAS-O and associated with inflammatory oxidative activities, and

has been implicated in cognitive impairment and AD[39]. Additionally, *ERCC1, ERCC2,* and *ERCC3* are

involved in nucleotide excision repair pathway contributing to genome stability[51, 52], which plays a critical

role during the development of the central nervous system[53] and whose impairment is associated with

AD[54]. Gene *PRPF19* that is interconnected with *ERCC1, ERCC2*, and *ERCC3* encodes a pre-mRNA

processing factor involved in regulating pre-mRNA splicing[55]. Prior studies indicated that *PRPF19* had a

neuronal function and was implicated in neurological diseases[56, 57]; lower expression level of gene

MRPL16 encoding a mitochondrial ribosome protein was observed in AD blood cells which may reflect a

general response to inflammatory environment in AD[58]; gene *ATPAF2* connected with *MRPL*16 encodes

a protein involved in mitochondrial function and lipid pathway, which has been implicated in dementia

pathogenesis[59].

PWAS-O still has its limitations. First, the CV R^2 is generally low for majority protein

abundance prediction models. This might be due to small sample sizes in the proteomics reference data,

or low heritability of protein abundances due to cis-SNPs. Only *cis*-SNPs within the $\pm 1MB$ region

around the test gene transcription starting and termination sites were considered as predictors for protein

abundances by PWAS-O. Trans-SNPs could also be considered as additional predictors in the protein

abundance prediction models, which might increase the CV R^2 of protein abundance imputation

models[8]. Second, the standard two-stage PWAS method cannot distinguish whether causal SNPs for the

phenotype of interest are only colocalized with pQTLs but have no mediation effect through the protein

abundances (i.e., horizontal pleiotropy) or indeed have genetic effects mediated by protein abundances

(i.e., vertical pleiotropy). Horizontal pleiotropy happens when genetic variants impact the outcome

through pathways different from or additional to the proteome abundances of the test gene[60]. Such an

issue can be alleviated by testing the vertical pleiotropy of PWAS risk genes by PMR-Egger tool[20], which

controls for possible horizontal pleiotropy.

In summary, PWAS-O represents the first omnibus PWAS method that increases power by

leveraging multiple standard two-stage PWAS tools. PWAS-O can be easily applied to integrating

reference proteomics data with publicly available large-scale GWAS summary data, for studying complex

polygenic diseases. We believe that PWAS-O would be useful for mapping risk genes with genetic effects

potentially mediated through proteome abundances for complex diseases. Identified PWAS risk genes

would shed light upon future studies of disease pathogenesis and therapeutics.

278
279 **Methods**
280
<u>**ROS/MAP Proteomics and WGS Data**</u>

Human brain proteomic profiles were generated from the dorsolateral prefrontal cortex (DLPFC)

of postmortem brain samples donated by 400 participants of European ancestry of the Religious Orders

Study or Rush Memory and Aging Project (ROS/MAP)[10, 24] . Participants in ROS and MAP enroll without

known dementia and agree to annual clinical evaluation and organ donation at death. All participants sign

an informed consent, Anatomic Gift Act and Repository Consent. Both studies were reviewed by an

Institutional Review Board of Rush University Medical Center. Age was calculated from birth date and

date of death. Sex was self-report. Protein measurements from the dorsolateral prefrontal cortex (DLPFC)

were quantified by tandem mass spectrometry.

As described in previous publication[61], protein abundances were normalized by scaling each

protein abundance with respect to a sample-specific total protein abundance, and proteins with missing

values in more than 50% of the participants were excluded from the analyses. Protein abundance ratios

related to baseline (sample-specific total protein abundance) were $\log_2$ transformed, with missing values

imputed by the corresponding mean of 400 samples. Confounding effects of clinical characteristics

including sex, age at death, postmortem interval, and study type (ROS or MAP), as well as technical

factors including sequencing batch and MS2 versus MS3 mass spectrometry reporter quantification mode,

were regressed out from protein abundances. Outlier samples were removed using iterative principal

component analysis (PCA) as shown in Fig. S1. That is, samples with top 2 PCs greater than the

corresponding four times of the standard deviations from the mean of each PC[61].

The genotype data of ROS/MAP samples were profiled by whole genome sequencing (WGS)[25].

SNPs with Hardy-Weinberg equilibrium p-values $<10^{-5}$ and minor allele frequency >1% were used as

genetic predictors for training the protein abundance imputation models. After quality control of both

proteomic and genetic data, a total of 355 samples with both proteomic and WGS data were used as the

reference data for PWAS-O in this study.

Summary-level GWAS data of AD dementia

The summary-level GWAS data of AD dementia (i.e., single variant Z-score test statistics

obtained by meta-analysis) were generated by the latest GWAS by Douglas et al[1], including 762,917

individuals from 12 cohorts that did not include 23&Me. About 11.3% of participants had clinically

diagnosed AD dementia.

Two-stage PWAS
313
As shown in **Fig. 1**, the two-stage PWAS first trains protein abundance imputation models (stage

I) by taking *cis*-genotype data, ±1MB around the corresponding gene transcription starting and

termination sites, as predictors (X), protein abundance level ($\mathbf{E}_p$) as the outcome, as shown in the

following linear regression model:

$$\mathbf{E}_p = \mathbf{Xw} + \boldsymbol{\epsilon}; \ \boldsymbol{\epsilon} \sim N(0, \sigma_\epsilon^2 \mathbf{I}).$$

Protein abundance level ($\mathbf{E}_p$) were residuals after regressing out individual characteristics and technical

factors from the profiled protein abundances (log2 transformed ratios as described in the above section).

The effect size vector $\mathbf{w}$ could be estimated by different statistical models as employed by TIGAR[23],

PrediXcan[13], and FUSION[4], which could be viewed as a broad sense of pQTL effect sizes (also referred

to as pQTL weights). Specifically, PrediXcan employs a penalized linear regression model with Elastic-

Net penalty[13]; FUSION[4] uses penalized linear regression model with Elastic-Net penalty and LASSO

penalty[16], regular linear regression model with best unbiased linear predictor (BLUP), single variant

model with Top pQTL (Top1), and Bayesian spare linear mixed model (BSLMM)[17], and then selects the

best model according to CV R^2; TIGAR[7] implements the nonparametric Bayesian latent DPR model.

In stage II, with individual-level GWAS data, the protein abundances will first be imputed by

using the trained imputation models and individual-level genotype data of test samples. Then PWAS will

test the association between the imputed protein abundances and the phenotype of interest. With summary

GWAS data, PWAS would take the pQTL weights estimated in stage I as variant weights to conduct

gene-based association test with GWAS Z-scores and reference LD. The PWAS test is equivalent to a

burden test with the following test statistic:

$$\tilde{Z}_{p,S\text{-}PrediXcan} = \frac{\sum_{l=1}^m (\widehat{w_l}\widehat{\sigma_l}Z_l)}{\sqrt{\widehat{\mathbf{w}}'\mathbf{V}\widehat{\mathbf{w}}}}, \quad \widehat{\sigma_l^2} = \mathrm{Var}(\mathbf{X_{0,l}}), \quad \mathbf{V} = \mathrm{Cov}(\mathbf{G_0}).$$

Here, $\widehat{w_l}$ denotes the pQTL effect size estimates from protein imputation models; Z_l denotes the Z-score

statistics of single variant l by GWAS test; and $\mathbf{V}$ denotes the LD covariance matrix from a reference

panel. The genotype variance $\widehat{\sigma_l}$ of test SNPs can also be estimated from a reference panel. Here the

reference panel is required to be of the same ancestry as the GWAS summary data, and could be the same

reference genotype data as used for training pQTL weights.

PWAS-O Method

As shown in **Fig. 2**, with PWAS p-values obtained by two-stage PWAS tools including TIGAR[23],

PrediXcan[13], and FUSION[4], PWAS-O uses the ACAT-O test[18] to aggregate these PWAS p-values to

generate an omnibus test p-value per protein/gene. The ACAT-O test statistic is given by

345
$$T = \frac{1}{K} \sum_{k=1}^{K} \tan\{(0.5 - p_k)\}\pi\}, \qquad \pi \approx 3.14;$$

346 where p_k is the PWAS p-value obtained by standard two-stage PWAS tools. Under null hypothesis, the p-

347 value p_k is uniformly distributed in $[0, 1]$ and the transformation $\tan\{(0.5 - p_k)\}$ is Cauchy distributed.

348 Thus, the null distribution of the test statistic T can be approximated by a Cauchy distribution[18] and the

349 corresponding PWAS-O p-value can be approximated by

350
$$pvalue_T \approx \frac{1}{2} - \frac{\{\arctan(T)\}}{\pi}.$$

PWAS of AD dementia

In this study, we used the ROS/MAP proteomics and WGS data of 355 samples as reference data

to train protein abundance imputation models. For each protein, we first used TIGAR tool to train

nonparametric Bayesian DPR model and Elastic-Net regression model (as used by PrediXcan), and then

used FUSION[4] tool to train LASSO, Elastic-Net, BLUP, and Top1 models and then selected the best

model according to the CV R^2. We did not train a BSLMM model due to its high computation cost for

WGS data, and we expect that the nonparametric Bayesian DPR model would account for the mixed

sparse and infinitesimal genetic architecture. The 5-fold CV was conducted for all protein abundance

imputation models. The average CV R^2 across 5 folds of validation data was used to select the best

performing FUSION model as well as filter protein abundance imputation models for the follow-up

PWAS.

Second, protein abundance imputation models with 5-fold CV R^2 >0.005 were considered as

valid, and the corresponding pQTL weights were used along with summary-level GWAS data of AD

dementia to test for PWAS risk genes[23]. Last, PWAS-O p-values were generated by aggregating PWAS p-

values obtained by using pQTL weights estimated by TIGAR (DPR), PrediXcan (Elastic-Net), and

FUSION (best model).

PPI network and pathway analysis

370
To investigate the PPI network among the identified PWAS risk genes of AD dementia, we used

STRING[42, 43], a website for PPI network analysis which integrates public data sources of protein

interaction information and investigates the connectivity network of proteins. Proteins are considered as

nodes in the PPI network. Protein-protein edges represent the predicted functional associations, colored

differently to indicate seven categories — co-expression, text-mining, experiments (biochemical/genetic

data), databases (previously curated pathway and protein complex information), gene co-occurrence, gene

fusion and neighborhood. Gene co-occurrence, fusion, and neighborhood represent association

predictions are based on whole-genome comparisons.

STRING also enables gene-set enrichment analysis with respect to Gene Ontology (GO)

annotations[62], KEGG pathways[63], Reactome pathways[64], and UniProt keywords[65]. Enrichment analysis is

to detect GO terms, pathways, or UniProt keywords that are significantly enriched with genes in the

network versus random genes, adjusting for FDR. STRING also shows significant association between

input proteins and human phenotypes based on Monarch Initiative[66], a system to organize genotype-

phenotype connections from multiple data sources.

Test Pleiotropy effects

We used the PMR-Egger[20] tool to test the vertical pleiotropy effect between the protein

abundance level of PWAS risk genes and AD dementia, while controlling for horizontal effect. The

Multi-SNP-based SMR[45, 67] software and its accompanying heterogeneity in dependent instruments

(HEIDI) were also implemented to test the causal effect, using multiple *cis*-pQTL SNPs. Reference LD

derived from ROS/MAP WGS data were used to implement both PMR-Egger and SMR-HEIDI methods.

Test cis-SNPs were pruned according to their LD correlation matrix. The threshold of $R^2 = 0.95$ was used

for implementing PMR-Egger and $R^2 = 0.99$ was used for implementing SMR-HEIDI. For each protein-

coding gene, only SNPs that have nominal eQTL p-value < 0.05 were tested by SMR-HEIDI.

TWAS-O of AD Dementia

TWAS p-values were first obtained by using reference transcriptomic data of ROS/MAP samples

and GWAS summary data by TIGAR and PrediXcan, and then used to derive TWAS-O p-values by

ACAT. The reference transcriptomic data include 465 ROS/MAP samples with both gene expression

data for DLPFC tissue (by RNA sequencing) and WGS genotype data profiled. Gene expression data in

the format of Transcripts Per Million (TPM) were log2 transformed and adjusted for age at death, sex,

postmortem interval, study (ROS or MAP), batch effects, RNA integrity number scores, cell type

proportions (with respect to oligodendrocytes, astrocytes, microglia, neurons), top five genotype principal

components, and top probabilistic estimation of expression residuals (PEER) factors by linear regression

models. The cell type proportions were derived by using CIBERSORT pipeline[68] with single-cell RNA-

seq transcriptome profiles from human brain tissues as the reference[69] to de-convolute bulk RNA-seq

data[70]. Only genes with >0.1 TPM in ≥10 samples were considered. Cis-SNPs within a 1MB window of

each gene that met the MAF threshold >1% and Hardy-Weinberg Equilibrium (HWE) threshold of p-

value>10^{-5} were used in the imputation model as predictors. Only genes with an average 5-fold cross

validation $R^2 \geq 0.005$ in the gene expression imputation models were analyzed in TWAS.

Acknowledgments

We are thankful to all participants and the staff at the Rush Alzheimer's Disease Center for making the

proteomics and WGS data of ROS/MAP samples available to the research community. This work was

supported by the National Institute of Health R35GM138313 (T.H., J.Y.). The ROS/MAP studies are

supported by P30AG10161, K01AG054700, R01AG15819, R01AG17917, R01AG56352; the Illinois

Department of Public Health; and the Robert C. Borwell Endowment Fund. The funding organizations

had no role in the design or conduct of the study; collection, management, analysis, or interpretation of

the data; or preparation, review, or approval of the manuscript.

Data availability

Proteomics, transcriptomics, and WGS data of ROS/MAP samples used in this manuscript are available

from Synapse (https://doi.org/10.7303/syn3219045). These data are available via the AD Knowledge

Portal (https://adknowledgeportal.org), subject to requirements for data access and data attribution as

provided in https://adknowledgeportal.org/DataAccess/Instructions. GWAS summary data of AD

dementia is available from https://ctg.cncr.nl/software/summary_statistics. Results of the pQTL weights

and PWAS summary data generated in this study will be deposited to Synapse after publication of this

work. Instructions for implementing PWAS-O are available through PWAS-O Github page

(https://github.com/tingyhu45/PWAS-O).

Ethics declarations

432 Both MAP and ROS studies were approved by the Institutional Review Board of Rush University

433 Medical Center. All individual-level data analyzed in this work were de-identified. Written informed

434 consent was obtained from all study participants as was an Anatomical Gift Act for organ donation.

435 ROSMAP resources can be requested at www.radc.rush.edu.

Competing interests

438 The authors declare no competing interests.

439
Supplementary information

441 The supplementary file contains 2 supplementary tables and 5 supplementary figures.

References

1. Wightman, D.P.*, et al.* A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276-1282 (2021).
2. De Jager, P.L.*, et al.* A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. *Scientific Data* **5**, 180142 (2018).
3. Liu, B., Gloudemans, M.J., Rao, A.S., Ingelsson, E. & Montgomery, S.B. Abundant associations with gene expression complicate GWAS follow-up. *Nat Genet* **51**, 768-769 (2019).
4. Gusev, A.*, et al.* Integrative approaches for large-scale transcriptome-wide association studies. *Nat Genet* **48**, 245-252 (2016).
5. Gockley, J.*, et al.* Brain transcriptome wide association study (TWAS) implicates 8 genes across 6 loci in Alzheimer's disease: Genetics: Genetics and omics of AD I. *Alzheimer's & Dementia* **16**, e044839 (2020).
6. Brandes, N., Linial, N. & Linial, M. PWAS: proteome-wide association study-linking genes and phenotypes by functional variation in proteins. *Genome Biol* **21**, 173 (2020).
7. Nagpal, S.*, et al.* TIGAR: An Improved Bayesian Tool for Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits. *Am J Hum Genet* **105**, 258-266 (2019).
8. Luningham, J.M.*, et al.* Bayesian Genome-wide TWAS Method to Leverage both cis- and trans-eQTL Information through Summary Statistics. *Am J Hum Genet* **107**, 714-726 (2020).
9. Tang, S.*, et al.* Novel Variance-Component TWAS method for studying complex human diseases with applications to Alzheimer's dementia. *PLoS Genet* **17**, e1009482 (2021).
10. Wingo, A.P.*, et al.* Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. *Nat Genet* **53**, 143-146 (2021).
11. Wingo, T.S.*, et al.* Brain proteome-wide association study implicates novel proteins in depression pathogenesis. *Nat Neurosci* **24**, 810-817 (2021).
12. Zhang, J.*, et al.* Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. *Nat Genet* **54**, 593-602 (2022).
13. Gamazon, E.R.*, et al.* A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet* **47**, 1091-1098 (2015).
14. Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **67**, 301-320 (2005).
15. Boyle, E.A., Li, Y.I. & Pritchard, J.K. An Expanded View of Complex Traits: From Polygenic to Omnigenic. *Cell* **169**, 1177-1186 (2017).
16. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. *Journal of the Royal Statistical Society. Series B (Methodological)* **58**, 267-288 (1996).
17. Zhou, X., Carbonetto, P. & Stephens, M. Polygenic modeling with bayesian sparse linear mixed models. *PLoS genetics* **9**, e1003264 (2013).
18. Liu, Y.*, et al.* ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant Analysis in Sequencing Studies. *Am J Hum Genet* **104**, 410-421 (2019).
19. Dai, Q.*, et al.* OTTERS: A powerful TWAS framework leveraging summary-level reference data. *bioRxiv*, 2022.2003.2030.486451 (2022).
20. Yuan, Z.*, et al.* Testing and controlling for horizontal pleiotropy with probabilistic Mendelian randomization in transcriptome-wide association studies. *Nat Commun* **11**, 3861 (2020).

21.   Zhu, Z*., et al.* Integration of summary data from GWAS and eQTL studies predicts
complex trait gene targets. *Nat Genet* **48**, 481-487 (2016).
22.   Wu, Y*., et al.* Integrative analysis of omics summary data reveals putative mechanisms
underlying complex traits. *Nat Commun* **9**, 918 (2018).
23.   Parrish, R.L., Gibson, G.C., Epstein, M.P. & Yang, J. TIGAR-V2: Efficient TWAS tool
with nonparametric Bayesian eQTL weights of 49 tissue types from GTEx V8. *HGG Adv* **3**,
100068 (2022).
24.   Bennett, D.A*., et al.* Religious Orders Study and Rush Memory and Aging Project. *J
Alzheimers Dis* **64**, S161-s189 (2018).
25.   De Jager, P.L*., et al.* A multi-omic atlas of the human frontal cortex for aging and
Alzheimer's disease research. *Scientific data* **5**, 1-13 (2018).
26.   Buniello, A*., et al.* The NHGRI-EBI GWAS Catalog of published genome-wide
association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005-
d1012 (2019).
27.   Marioni, R.E*., et al.* GWAS on family history of Alzheimer's disease. *Transl Psychiatry*
8, 99 (2018).
28.   Jansen, I.E*., et al.* Genome-wide meta-analysis identifies new loci and functional
pathways influencing Alzheimer's disease risk. *Nat Genet* **51**, 404-413 (2019).
29.   Kim, S*., et al.* Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and
p-tau181p in the ADNI cohort. *Neurology* **76**, 69-79 (2011).
30.   Schwartzentruber, J*., et al.* Genome-wide meta-analysis, fine-mapping and integrative
prioritization implicate new Alzheimer's disease risk genes. *Nat Genet* **53**, 392-402 (2021).
31.   Gouveia, C*., et al.* Genome-wide association of polygenic risk extremes for Alzheimer's
disease in the UK Biobank. *Sci Rep* **12**, 8404 (2022).
32.   Davies, G*., et al.* Study of 300,486 individuals identifies 148 independent genetic loci
influencing general cognitive function. *Nat Commun* **9**, 2098 (2018).
33.   Lee, J.J*., et al.* Gene discovery and polygenic prediction from a genome-wide association
study of educational attainment in 1.1 million individuals. *Nat Genet* **50**, 1112-1121 (2018).
34.   Wang, H*., et al.* Genome-wide interaction analysis of pathological hallmarks in
Alzheimer's disease. *Neurobiol Aging* **93**, 61-68 (2020).
35.   Hao, S., Wang, R., Zhang, Y. & Zhan, H. Prediction of Alzheimer's Disease-Associated
Genes by Integration of GWAS Summary Data and Expression Data. *Front Genet* **9**, 653 (2018).
36.   Gockley, J*., et al.* Multi-tissue neocortical transcriptome-wide association study
implicates 8 genes across 6 genomic loci in Alzheimer's disease. *Genome Med* **13**, 76 (2021).
37.   Gerring, Z., Lupton, M., Edey, D., Gamazon, E. & Derks, E. An analysis of genetically
regulated gene expression across multiple tissues implicates novel gene candidates in
Alzheimer's disease. *Alzheimer's Research & Therapy* **12**, 43 (2020).
38.   Sun, Y*., et al.* A transcriptome-wide association study of Alzheimer's disease using
prediction models of relevant tissues identifies novel candidate susceptibility genes. *Genome
Medicine* **13**, 141 (2021).
39.   Davidson, J.E*., et al.* Plasma lipoprotein-associated phospholipase A2 activity in
Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly
subjects: a cross-sectional study. *Alzheimers Res Ther* **4**, 51 (2012).
40.   Drenos, F*., et al.* Integrated associations of genotypes with multiple blood biomarkers
linked to coronary heart disease risk. *Hum Mol Genet* **18**, 2305-2316 (2009).

41.   Dumont, V. & Lehtonen, S. PACSIN proteins in vivo: Roles in development and
physiology. *Acta Physiol (Oxf)* **234**, e13783 (2022).
42.   Szklarczyk, D*., et al.* STRING v11: protein–protein association networks with increased
coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids*
Research **47**, D607-D613 (2018).
43.   Szklarczyk, D*., et al.* The STRING database in 2021: customizable protein-protein
networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic*
Acids Res **49**, D605-d612 (2021).
44.   Jong, M.C., Hofker, M.H. & Havekes, L.M. Role of ApoCs in Lipoprotein Metabolism.
Arteriosclerosis, Thrombosis, and Vascular Biology **19**, 472-484 (1999).
45.   Zhu, Z*., et al.* Integration of summary data from GWAS and eQTL studies predicts
complex trait gene targets. *Nature Genetics* **48**, 481-487 (2016).
46.   Myklebost, O. & Rogne, S. The gene for human apolipoprotein CI is located 4.3
kilobases away from the apolipoprotein E gene on chromosome 19. *Hum Genet* **73**, 286-289
(1986).
47.   Smit, M., van der Kooij-Meijs, E., Frants, R.R., Havekes, L. & Klasen, E.C.
Apolipoprotein gene cluster on chromosome 19. Definite localization of the APOC2 gene and
the polymorphic Hpa I site associated with type III hyperlipoproteinemia. *Hum Genet* **78**, 90-93
(1988).
48.   Lauer, S.J*., et al.* Two copies of the human apolipoprotein C-I gene are linked closely to
the apolipoprotein E gene. *J Biol Chem* **263**, 7277-7286 (1988).
49.   Saunders, A.M*., et al.* Association of apolipoprotein E allele ϵ4 with late-onset familial
and sporadic Alzheimer's disease. *Neurology* **43**, 1467-1467 (1993).
50.   Panza, F*., et al.* Lipid metabolism in cognitive decline and dementia. *Brain Res Rev* **51**,
275-292 (2006).
51.   Wood, R.D., Mitchell, M., Sgouros, J. & Lindahl, T. Human DNA repair genes. *Science*
291, 1284-1289 (2001).
52.   Weeda, G*., et al.* A presumed DNA helicase encoded by ERCC-3 is involved in the
human repair disorders xeroderma pigmentosum and Cockayne's syndrome. *Cell* **62**, 777-791
(1990).
53.   Fishel, M.L., Vasko, M.R. & Kelley, M.R. DNA repair in neurons: so if they don't divide
what's to repair? *Mutat Res* **614**, 24-36 (2007).
54.   Weissman, L*., et al.* Defective DNA base excision repair in brain from individuals with
Alzheimer's disease and amnestic mild cognitive impairment. *Nucleic Acids Research* **35**, 5545-
5555 (2007).
55.   Ajuh, P*., et al.* Functional analysis of the human CDC5L complex and identification of its
components by mass spectrometry. *Embo j* **19**, 6569-6581 (2000).
56.   Urano, Y*., et al.* Involvement of the mouse Prp19 gene in neuronal/astroglial cell fate
decisions. *J Biol Chem* **281**, 7498-7514 (2006).
57.   Yamada, T*., et al.* The U-box-type ubiquitin ligase PRP19β regulates astrocyte
differentiation via ubiquitination of PTP1B. *Brain Res* **1524**, 12-25 (2013).
58.   Lunnon, K*., et al.* Mitochondrial genes are altered in blood early in Alzheimer's disease.
Neurobiol Aging **53**, 36-47 (2017).
59.   Reynolds, C.A*., et al.* Analysis of lipid pathway genes indicates association of sequence
variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. *Human Molecular Genetics* **19**,
2068-2078 (2010).

60.   Verbanck, M., Chen, C.Y., Neale, B. & Do, R. Detection of widespread horizontal
pleiotropy in causal relationships inferred from Mendelian randomization between complex traits
and diseases. *Nat Genet* **50**, 693-698 (2018).
61.   Wingo, A.P.*, et al.* Shared proteomic effects of cerebral atherosclerosis and Alzheimer's
disease on the human brain. *Nature Neuroscience* **23**, 696-700 (2020).
62.   The Gene Ontology Resource: 20 years and still GOing strong. *Nucleic Acids Res* **47**,
D330-d338 (2019).
63.   Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a
reference resource for gene and protein annotation. *Nucleic Acids Res* **44**, D457-462 (2016).
64.   Jassal, B.*, et al.* The reactome pathway knowledgebase. *Nucleic Acids Res* **48**, D498-
d503 (2020).
65.   UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* **47**, D506-d515
(2019).
66.   Mungall, C.J.*, et al.* The Monarch Initiative: an integrative data and analytic platform
connecting phenotypes to genotypes across species. *Nucleic Acids Res* **45**, D712-d722 (2017).
67.   Wu, Y.*, et al.* Integrative analysis of omics summary data reveals putative mechanisms
underlying complex traits. *Nature Communications* **9**, 918 (2018).
68.   Newman, A.M.*, et al.* Robust enumeration of cell subsets from tissue expression profiles.
Nat Methods **12**, 453-457 (2015).
69.   Darmanis, S.*, et al.* A survey of human brain transcriptome diversity at the single cell
level. *Proc Natl Acad Sci U S A* **112**, 7285-7290 (2015).
70.   Wingo, T.S.*, et al.* Brain microRNAs associated with late-life depressive symptoms are
also associated with cognitive trajectory and dementia. *NPJ Genom Med* **5**, 6 (2020).
601
602
603

Tables

Table 1. Trained protein abundance imputation models with CV $R^2 > 0.005$ from ROS/MAP reference data, by TIGAR, PrediXcan, and FUSION tools.

Model	N	CV R^2 median
TIGAR	6673	0.013
PrediXcan	1835	0.0094
FUSION	2173	0.0093

Table 2. Independent PWAS-O risk genes of AD dementia. Missing P-values denoted by dashes are due to either CV $R^2 < 0.5\%$ for the corresponding protein abundance imputation models or no trained protein abundance imputation model by PrediXcan (because of variable selection).

Gene	CHR	PWAS-O P-value	TIGAR P-value	PrediXcan P-value	FUSION P-value
CDC42[c]	1	2.47×10^{-4}	2.47×10^{-4}	-	-
ERCC3[b]	2	2.91×10^{-4}	1.80×10^{-4}	-	7.54×10^{-4}
MGAT5	2	6.38×10^{-5}	7.62×10^{-4}	2.19×10^{-5}	2.97×10^{-2}
HSPA1B[b]	6	2.64×10^{-9}	-	-	2.64×10^{-9}
TULP1[b]	6	2.88×10^{-4}	4.14×10^{-1}	-	1.44×10^{-4}
PLA2G7[c]	6	9.03×10^{-5}	9.03×10^{-5}	-	-
MAP3K7	6	5.71×10^{-5}	5.71×10^{-5}	-	-
TRIM4[b]	7	3.72×10^{-5}	3.72×10^{-5}	-	-
AGFG2[a,b,c]	7	9.86×10^{-8}	1.24×10^{-7}	-	8.20×10^{-8}
ZYX[b,c]	7	1.39×10^{-5}	7.91×10^{-6}	5.86×10^{-5}	-
C1QTNF4[b,c]	11	2.24×10^{-5}	2.24×10^{-5}	-	-
MRPL16[b,c]	11	8.66×10^{-15}	4.33×10^{-15}	1.31×10^{-2}	-
CCDC86[b]	11	2.83×10^{-9}	1.42×10^{-9}	-	1.59×10^{-1}
DIABLO	12	9.26×10^{-5}	9.26×10^{-5}	-	-
ATPAF2[b]	17	8.20×10^{-5}	8.20×10^{-5}	-	-
DCAKD[b]	17	6.19×10^{-5}	3.62×10^{-3}	-	3.12×10^{-5}
CLPTM1[a,b,c]	19	1.44×10^{-70}	1.49×10^{-21}	7.21×10^{-71}	-
SPHK2[c]	19	1.76×10^{-4}	4.87×10^{-2}	8.82×10^{-5}	-
YWHAB	20	1.71×10^{-4}	1.71×10^{-4}	-	-

a known GWAS risk genes of AD dementia.
b known TWAS risk genes of AD dementia, or test region overlapped with TWAS risk genes.
c significant mediated causal genetic effects by PMR-Egger or SMR.

Figures Titles and Legends

Fig.1: Two-stage PWAS framework.
Stage I: Protein abundance imputation models are trained using *cis*-SNPs as predictors and proteomic abundance as the outcome, which estimates pQTL effect sizes (weights) per protein-coding gene. Stage II: Individual PWAS predicts the protein abundances using the trained imputation models and individual-level genotype data of test samples, and then tests the association between the predicted protein abundance and the trait of interest. Summary-based PWAS takes the pQTL effect sizes as variant weights to conduct gene-based association test with GWAS Z-scores and reference LD.

Fig. 2: PWAS-O framework.
First, train protein abundance imputation models using reference data and conduct two-stage PWAS (**Fig. 1**) using GWAS data by TIGAR, PrediXcan, and FUSION tools. Second, implement ACAT-O with all PWAS p-values to obtain a PWAS-O p-value per protein-coding gene.

Fig. 3: Manhattan plot of PWAS-O results for AD dementia.
A total of 43 significant risk genes were identified with FDR q-value < 0.05. A total of 19 independently significant genes were labeled. The -log10(q-values) were plotted in the y-axis, and -log10(0.05) was plotted as the dashed horizontal line.

Fig. 4: pQTL weights estimated by TIGAR (DPR) and FUSION (best model of LASSO, Elastic-Net, BLUP, Top1) for example significant genes *PPM1N* (A) and *DCAKD* (B) by PWAS-O.
The pQTL weights were plotted in the y-axis for all test SNPs in the test gene region, with color coded with respect to their -log10 (GWAS p-value). SNPs with $-\log10(\text{GWAS p-value}) < 10^{-5}$ were plotted in yellow color. Gene *PPM1N* was found significant by both TIGAR and FUSION, as multiple test SNPs with non-zero pQTL weights (by TIGAR and FUSION) were colocalized with significant GWAS SNPs (yellow dots). Whereas, the significance of *DCAKD* was mainly driven by FUSION, for having fewer SNPs with significant GWAS p-values that are also colocalized with a relatively large magnitude of pQTL weights.

Fig. 5: PPI networks and enriched pathways among 43 PWAS risk genes of AD dementia by STRING.
Edges represent physical PPI, with different colors representing different sources of connection evidence. Node colors represent different enriched GO terms or KEGG pathways with FDR < 0.05.

Reference Panel

N samples

SNPs

TTGTCACATG
TACAGACTTG
AGTGTATCGA
ATGTGATAGA
TGTAGTAATT

~

M proteins

Proteomic Abundance

N samples

pQTL Weights (SNP level)

$\mathbf{w}_{1,p_1} \ldots \mathbf{w}_{l,p_1}$

$\mathbf{w}_{1,p_2} \ldots \mathbf{w}_{l,p_2}$

$\mathbf{w}_{1,p_3} \ldots \mathbf{w}_{l,p_3}$

$\mathbf{w}_{1,p_m} \ldots \mathbf{w}_{l,p_m}$

Individual PWAS

SNPs

TTGTCACATG
TACAGACTTG
AGTGTATCGA
ATGTGATAGA
TGTAGTAATT

Predicted Protein Abundance

Trait

~

Summary-based PWAS

GWAS Z-Scores (SNP-level)

Z_1 Z_2 Z_3 Z_4

Reference LD

Gene-based Association Test by Weighted Sum of GWAS Z-Scores with pQTL Weights and Reference LD

Connections:

- *From curated databases*
- *Experimentally determined*
- *Textmining*
- *Co-expression*
- *Gene fusions*
- *Gene neighborhood*

Enriched pathways

- *UV protection (GO:0009650, FDR = 0.0101)*
- *Adherens junction (hsa04520, FDR = 0.0124)*
- *Transcription-coupled nucleotide-excision repair (GO:0006283, FDR = 0.0131)*
- *Plasma lipoprotein particle remodeling (GO:0034369, FDR = 0.0138)*
- *Negative regulation of very-low-density lipoprotein particle clearance (GO:0043933, FDR = 0.0181)*
- *Protein-containing complex subunit organization (GO:0043933, FDR = 0.0255)*